<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31276" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vulva Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Capria</surname>
            <given-names>Anthony</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tahir</surname>
            <given-names>Nayha</given-names>
          </name>
          <aff>Northwestern hospital Mchenry IL, Rosalind Franklin University, Chicago Medical School</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fatehi</surname>
            <given-names>Mary</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anthony Capria declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nayha Tahir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mary Fatehi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>9</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31276.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Vulvar cancer represents 0.3% of all new cancer cases in the United States. Squamous cell carcinoma is the most common type, usually diagnosed at ages 65 to 74. Risk factors include increasing age, HPV infection, smoking, inflammatory conditions of the vulva, prior pelvic radiation, and immunodeficiency. It usually presents as an erythematous lesion or an ill-defined mass. Diagnosis is usually made via tissue biopsy, with surgical excision being the mainstay of treatment. Adjuvant chemo and radiotherapy can also be considered depending on the stage of the disease. This activity reviews the evaluation and management of vulvar Cancer and highlights the healthcare team's role in evaluating and treating patients with vulvar cancer.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of vulvar cancer.</p></list-item><list-item><p>Evaluate&#x000a0;the pathophysiology of vulvar cancer.</p></list-item><list-item><p>Differentiate&#x000a0;the management options available for vulvar cancer.</p></list-item><list-item><p>Communicate&#x000a0;some interprofessional team strategies to improve patient outcomes in vulvar cancer cases.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31276&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31276">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31276.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>According to the&#x000a0;Surveillance, Epidemiology, and End Results (SEER) Program, vulvar cancer represents 0.3% of all new cancer cases annually at a rate of 2.6 per 100,000 women per year in the United States. Diagnosis is usually made in the sixth through eighth decades of life and is commonly identified early in the disease. Squamous cell carcinoma (SCC) accounts for most vulvar cancers, while basal cell carcinoma (BCC), extramammary Paget disease, and vulvar melanoma comprise the less common subtypes. Surgery remains the mainstay of vulvar cancer treatment, with medical and radiation oncology playing an increasingly important role in preventing recurrence and improving outcomes.<xref ref-type="bibr" rid="article-31276.r1">[1]</xref><xref ref-type="bibr" rid="article-31276.r2">[2]</xref></p>
      </sec>
      <sec id="article-31276.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Risk factors for the development of vulvar cancer include increasing age, infection with human papillomavirus (HPV), smoking, inflammatory conditions of the vulva, prior pelvic radiation, and immunodeficiency.<xref ref-type="bibr" rid="article-31276.r3">[3]</xref></p>
      </sec>
      <sec id="article-31276.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Squamous cell carcinoma is the most common type of vulvar cancer.<xref ref-type="bibr" rid="article-31276.r1">[1]</xref> SEER data supports that&#x000a0;vulvar cancer is most commonly diagnosed at ages 65&#x000a0;to 74, with the median age at diagnosis of 69 years. The data notes&#x000a0;that sixty percent of diagnoses are localized and exhibit an 85% five-year survival. Vulvar melanoma is the second most common vulvar malignancy, representing 5% of vulvar cancers.<xref ref-type="bibr" rid="article-31276.r4">[4]</xref> It more commonly affects White race women ages 50&#x000a0;to 70. The median age at diagnosis for vulvar melanoma is similar to SCC (68 years), but approximately 8.4% present with advanced disease and have a lower survival rate.<xref ref-type="bibr" rid="article-31276.r5">[5]</xref></p>
      </sec>
      <sec id="article-31276.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Vulvar SCC represents 90% of all vulvar cancers and typically develops by one of two pathways (see <bold>Image.</bold> Vulvar Cancer Development).<xref ref-type="bibr" rid="article-31276.r6">[6]</xref>&#x000a0;Thirty to forty percent of vulvar cancer cases are associated with high-risk human papillomavirus (HR-HPV), resulting from the classic &#x0201c;two-hit hypothesis&#x0201d; for cancer development.<xref ref-type="bibr" rid="article-31276.r6">[6]</xref><xref ref-type="bibr" rid="article-31276.r7">[7]</xref>&#x000a0;HPV is known to have E6 and E7 oncoproteins, which inactivate the p53 and RB tumor suppressor proteins, respectively. The loss of these tumor suppressor genes leads to unregulated hyperproliferation. Another pathway involves inflammatory changes that result in cells with intact p53 status but the loss of cyclin-dependent kinase inhibitor 2A (p16), also resulting in unregulated cell cycle proliferation and eventually cancer (see <bold>Image.</bold> Human Papillomavirus [HPV 16]).<xref ref-type="bibr" rid="article-31276.r2">[2]</xref><xref ref-type="bibr" rid="article-31276.r7">[7]</xref><xref ref-type="bibr" rid="article-31276.r8">[8]</xref>&#x000a0;Pathophysiology of usual-type and differentiated VIN and its progression to SCC. Suggested progression of usual-type (uVIN) and differentiated vulvar intraepithelial neoplasia (dVIN) to SCC.<xref ref-type="bibr" rid="article-31276.r2">[2]</xref></p>
      </sec>
      <sec id="article-31276.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p><bold>Squamous Cell Carcinoma</bold>: Squamous cell carcinoma is the most common histologic subtype of vulvar cancer (see <bold>Image.</bold> Vulvar Squamous Cell Carcinoma). The precursor lesion for SCC is vulvar intraepithelial neoplasia (VIN) and can be subdivided into two categories: HPV-dependent usual type (uVIN) and HPV-independent differentiated type (VIN).<xref ref-type="bibr" rid="article-31276.r2">[2]</xref>&#x000a0;As of 2012, the Lower Anogenital Squamous Terminology unified terminology for all HPV-associated squamous lesions and recommended the use of Low-Grade Squamous Intraepithelial Lesions (LSIL) and High-Grade Squamous Intraepithelial Lesions (HSIL).<xref ref-type="bibr" rid="article-31276.r9">[9]</xref>&#x000a0;In 2014, the WHO classification of tumors subdivided squamous intraepithelial lesions of the vulva into LSIL, HSIL, and dVIN. In 2015, the International Society for the Study of Vulvovaginal Disease (ISSVD) accepted and approved a similar terminology classification.<xref ref-type="bibr" rid="article-31276.r10">[10]</xref></p>
        <p><bold>uVIN: </bold>(LSIL, HSIL). This is the HPV-dependent usual type that typically affects younger patients and is less likely to progress to SCC than dVIN.<xref ref-type="bibr" rid="article-31276.r10">[10]</xref><xref ref-type="bibr" rid="article-31276.r11">[11]</xref>&#x000a0;There is a strong association between this subtype and a history of smoking, and it is more commonly seen in basaloid or warty SCC. This subtype is usually p16 positive and p53 negative on immunohistochemistry, whereas dVIN is usually p16 negative and p53 positive.<xref ref-type="bibr" rid="article-31276.r12">[12]</xref>&#x000a0;The usual type of VIN progresses to invasive SCC in only 5% of cases but is responsible for 40% of all vulvar SCC.<xref ref-type="bibr" rid="article-31276.r6">[6]</xref></p>
        <p><bold>dVIN:</bold> HPV-independent differentiated type typically progresses to keratinized SCC (see <bold>Image.</bold> Vulvar Squamous Cell Carcinoma, Histopathology). This subtype arises mostly from chronic dermatoses, with lichen sclerosis and lichen planus being the most common.<xref ref-type="bibr" rid="article-31276.r2">[2]</xref> It is characterized by cellular atypia of the basal layers of the vulvar epithelium. dVIN makes up only 5% of preinvasive vulvar lesions but has a higher rate of malignant transformation than uVIN and is identified as a precursor in approximately 35% of vulvar SCC.<xref ref-type="bibr" rid="article-31276.r9">[9]</xref>&#x000a0;Patients with lichen sclerosus need lifelong monitoring due to the risk of eventually developing vulvar SCC, increasing the duration of the disease (1% at 2 years with lichen sclerosus and 37% at 25 years with the disease).<xref ref-type="bibr" rid="article-31276.r13">[13]</xref>&#x000a0;See <bold>Image.</bold> Kraurosis Vulvae,&#x000a0;Lichen&#x000a0;Sclerosus, Pathology.&#x000a0;</p>
        <p>Vulvar SCC can be categorized into three histological subtypes: warty, basaloid, and keratinizing. A warty and basaloid subtype is found mostly in patients ages 40&#x000a0;to 44 years and is associated with HPV. The keratinizing subtype is associated with older patients and is HPV-independent. This type accounts for 60-80% of all SCC subtypes. It may occur anywhere on the vulva but is most commonly found on the labia majora and perineum.</p>
        <p><bold>Basal Cell Carcinoma:</bold> Basal cell carcinoma is a relatively rare vulvar malignancy. Approximately 2% of BCC affects the vulva, and vulvar BCC is diagnosed in only 8% of all vulvar malignancies.<xref ref-type="bibr" rid="article-31276.r14">[14]</xref> Diagnosis of vulvar BCC is usually made in a seventh or eighth decade, most commonly with a labia majora and vulvar pruritis lesion.<xref ref-type="bibr" rid="article-31276.r9">[9]</xref> Most BCC is of the nodular subtype, with the superficial subtype being the second most common. Dermoscopy diagnostic of BCC reveals arborizing vessels, telangiectasias, blue ovoid nests, blue globules, and shiny white structures. Imaging studies are only needed for extensive local disease suspicious for underlying structural destruction and invasion. Analogous to BCC in other body areas, treatment is the primary complete excision with negative margins. BCC in the genital area is at high risk for recurrence; however, the prognosis of vulvar BCC is favorable, and overall survival is unaffected by the lesion's size. The Mohs surgical technique has been used successfully with a 3-year recurrence-free survival rate of 100%.<xref ref-type="bibr" rid="article-31276.r15">[15]</xref></p>
        <p><bold>Paget Disease: </bold>Extramammary Paget disease is a rare skin malignancy affecting the apocrine gland-bearing skin, with 65% of all cases occurring in the vulva<xref ref-type="bibr" rid="article-31276.r16">[16]</xref>, comprising only 1-2% of all vulvar malignancies.<xref ref-type="bibr" rid="article-31276.r17">[17]</xref> This disease occurs primarily in Caucasian women in their sixth to seventh decade of life. Pruritis is the presenting symptom in 54%<xref ref-type="bibr" rid="article-31276.r18">[18]</xref> to 72%<xref ref-type="bibr" rid="article-31276.r19">[19]</xref>. Vulvar Paget disease can be broadly categorized as a primary or secondary disease. Primary vulvar Paget disease is an intraepithelial adenocarcinoma with Paget cells that arise from within the epidermis and extend into the epithelium of adjacent skin appendages.<xref ref-type="bibr" rid="article-31276.r20">[20]</xref> This disease can become locally invasive when Paget cells break through the basement membrane and infiltrate deeper tissue layers. Secondary vulvar Paget disease occurs less frequently but is associated with epidermotropic metastases or direct invasion of an occult adenocarcinoma. Noninvasive vulvar Paget disease is associated with underlying adenocarcinoma in 4-17% of patients.<xref ref-type="bibr" rid="article-31276.r18">[18]</xref><xref ref-type="bibr" rid="article-31276.r19">[19]</xref><xref ref-type="bibr" rid="article-31276.r21">[21]</xref>Histologically, Paget cells are epithelial tumor cells with clear cytoplasm. These can either heterogeneously invade the epidermis or spread in a nest-like fashion. Immunohistochemical (IHC) markers of vulvar Paget disease include Cytokeratin 7, CEA, pan-CK, and EMA. IHC markers CK20 and CDX2 are more prevalent in secondary vulvar Paget disease and can help differentiate primary from secondary disease. Vulvar Paget lesions can be slow-growing for many years, but after invasion through the dermis, the spread can be rapid and aggressive via lymphatic or hematogenous routes. The adnexal extension is frequent, occurring in up to 90% of recurrent cases, most commonly involving hair follicles and eccrine ducts.<xref ref-type="bibr" rid="article-31276.r22">[22]</xref></p>
        <p><bold>Vulvar Melanoma: </bold>Three types of vulvar melanomas exist. The mucosal lentigous subtype is most common, followed by the nodular and superficial spreading subtypes. This differs from cutaneous melanoma, where the superficial spreading subtype is most common.<xref ref-type="bibr" rid="article-31276.r23">[23]</xref> Vulvar and cutaneous melanomas share similar IHC markers (S100B, HMB45, and Melan-A) that differ significantly by mutational analyses. Vulvar melanomas more rarely exhibit V600-BRAF mutations (7%<xref ref-type="bibr" rid="article-31276.r24">[24]</xref> to 26%<xref ref-type="bibr" rid="article-31276.r25">[25]</xref>) than mucosal melanomas, while mutations in cell regulatory proteins such as c-KIT and PD-L1 are significantly more common in vulvar melanoma, approximating 25-31%.<xref ref-type="bibr" rid="article-31276.r24">[24]</xref><xref ref-type="bibr" rid="article-31276.r25">[25]</xref>&#x000a0;In the fifth to seventh decades, white women are most commonly affected with lesions most often found on the clitoris and labia minora. The American Joint Committee on Cancer (AJCC) staging provides the best predictor for survival, with Breslow depth of invasion and lymphovascular space invasion predictive of nodal metastases.<xref ref-type="bibr" rid="article-31276.r26">[26]</xref> Surgical resection with adjuvant-targeted medical therapy is currently recommended.<xref ref-type="bibr" rid="article-31276.r27">[27]</xref></p>
        <p><bold>Verrucous Carcinoma: </bold>The etiology of vulvar verrucous carcinoma (VC) is unknown, and no precursor lesions to this disease have been described. However, an association between lichen simplex chronicus and lichen sclerosus has been reported.<xref ref-type="bibr" rid="article-31276.r28">[28]</xref> Studies evaluating an association with HPV status are mixed. Histologically, VC is a well-differentiated tumor with marked acanthotic epithelial proliferation and minimal nuclear atypia. The tumor expands with elongating rete ridges that have become characteristic of this type of lesion. These elongating ridges advance into the dermis, causing a pushing rather than infiltrating pattern.<xref ref-type="bibr" rid="article-31276.r2">[2]</xref> Proliferation occurs primarily at basal and parabasal layers. The increased expression of cellular proteins Ki67, MCM2, and TOP2A demonstrates this.<xref ref-type="bibr" rid="article-31276.r29">[29]</xref> In contrast with SCC, VC does not have overexpression of p53.<xref ref-type="bibr" rid="article-31276.r30">[30]</xref>&#x000a0;The appearance of these lesions is typically warty and can become quite large without the risk of metastasis. The recommended treatment is local excision.<xref ref-type="bibr" rid="article-31276.r30">[30]</xref></p>
        <p><bold>Sarcoma: </bold>Although rare, cancers of mesenchymal origin have been described in the setting of vulvar cancer. The most common sarcoma of the vulva is leiomyosarcoma (LMS), followed by dermatofibrosarcoma protuberans (DFSP), epithelioid sarcoma, malignant fibrohistiocytomas, and synovial sarcomas. Synovial sarcomas are divided into monophasic, biphasic, and undifferentiated histologic types. Monophasic contains only spindle cells, biphasic type contains both epithelial and spindle cell types, while undifferentiated share characteristics of both. Vulvar sarcomas are slow-growing tumors, most commonly of the clitoris and labia minora, have a younger age at diagnosis (median age 41 years) and rare lymph node invasion.<xref ref-type="bibr" rid="article-31276.r31">[31]</xref> DFSP median age at diagnosis is 45 years old and is related to a translocation leading to tyrosine kinase disinhibition. This presents a possible use for tyrosine kinase inhibitors in managing this subtype of vulvar sarcoma.<xref ref-type="bibr" rid="article-31276.r32">[32]</xref> Vulvar epithelioid sarcoma is diagnosed at the youngest mean age (31 years) and tends to exhibit the lowest survival of all vulvar cancers.<xref ref-type="bibr" rid="article-31276.r33">[33]</xref></p>
        <p><bold>Bartholin Gland and Other Adenocarcinomas:&#x000a0;</bold>The Bartholin gland's primary cancer is exceedingly rare and arises from either the gland or duct. Presentation is usually the growth of a painless mass in the labia majora during the 5 to 6 decades. Cancer of the Bartholin&#x02019;s gland most commonly exhibits either SCC or adenocarcinoma histologic subtypes.<xref ref-type="bibr" rid="article-31276.r34">[34]</xref><xref ref-type="bibr" rid="article-31276.r35">[35]</xref></p>
      </sec>
      <sec id="article-31276.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The anatomy of the vulva includes the mons pubis, labia majora, labia minora, clitoris, vestibule, vestibular bulb, and the greater vestibular glands. The internal and external pudendal arteries are responsible for most of the vulvar blood supply. The ilioinguinal, genitofemoral, and pudendal nerves are responsible for the innervation of the vulvar tissue. Vulvar lymphatic drainage is via the inguinal lymph nodes. The first lymphatic chain encountered is the superficial inguinal nodes. Then, after crossing through the cribriform fascia, lymphatic drainage is to the deep inguinal nodes, followed by the external iliac nodes and, finally, the paraaortic nodes. History of vulvar illness may include pruritis, irritation, or pain, but the patient can also be asymptomatic. Most patients with vulvar melanoma present with advanced symptoms, including bleeding, mass, and ulceration.<xref ref-type="bibr" rid="article-31276.r9">[9]</xref></p>
        <p>Approximately 25% of vulvar melanomas are amelanotic, making diagnosis difficult in many patients.<xref ref-type="bibr" rid="article-31276.r36">[36]</xref> Vulvar Paget disease can have a very nonspecific presentation, which has often led to the diagnosis being delayed by a median of two years, typically after topical steroids or antifungals have failed. Similarly, Bartholin&#x02019;s gland carcinoma presents nonspecifically as a painless visible tumor and is often misdiagnosed and incorrectly treated as an abscess or cyst before a definitive diagnosis.<xref ref-type="bibr" rid="article-31276.r34">[34]</xref>&#x000a0;A physical exam may show an erythematous lesion, a scaly patch, plaques, an ulcer, or an ill-defined mass. Lesions of verrucous carcinoma commonly have a cauliflower-like appearance. Any suspicious lesions warrant further investigation, including a pelvic exam, speculum exam, colposcopy of the vulva and vagina, and biopsy.<xref ref-type="bibr" rid="article-31276.r37">[37]</xref> In cases of vulvar melanoma, attention to the ABCDE rule (a dermatologic acronym for asymmetry, border irregularity, color, diameter, and evolving) can aid in clinical diagnosis.<xref ref-type="bibr" rid="article-31276.r38">[38]</xref></p>
      </sec>
      <sec id="article-31276.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The gold standard for diagnosing vulvar cancer remains histologic diagnosis, although clinical correlation does have significant value. Any suspicious lesion should be biopsied and carefully examined for its precise anatomical position with respect to the midline and distance from the vaginal introitus; this is crucial for planned surgical management. Imaging studies may be indicated to evaluate the extent of the disease. If there is suspicion of bladder or rectal involvement, cystoscopy and proctoscopy should be performed.<xref ref-type="bibr" rid="article-31276.r37">[37]</xref> In Paget disease, screening should be done for other malignancies, including genitourinary, gastrointestinal, and breast cancer, especially considering that the most common cause of secondary vulvar Paget disease is anorectal and urothelial adenocarcinomas.<xref ref-type="bibr" rid="article-31276.r39">[39]</xref></p>
      </sec>
      <sec id="article-31276.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Surgical excision is the standard therapy for vulvar cancer, but adjuvant radiation and chemotherapy may be recommended depending on the histopathology and extent of the disease.</p>
      </sec>
      <sec id="article-31276.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for vulvar cancer is broad due to the sometimes nonspecific nature of this disease. Several diseases that can mimic vulvar cancer include cutaneous SCC, cutaneous BCC, cutaneous melanoma, atopic dermatitis, psoriasis, lichen sclerosus, lichen planus, lichen chronicus simplex, contact dermatitis, candidiasis, pemphigus vegetans, or mycosis fungoides. Image 8.&#x000a0;Pathology, Kraurosis vulvae, lichen sclerosus, Chronic inflammatory dermatosis, white plaque, vulva, precancerous, squamous cell carcinoma, Urogenital, Genitalia, Vulvar Diseases (Contributed by Dr. N.J. Fiumara, The Centers for Disease Control and Prevention)</p>
      </sec>
      <sec id="article-31276.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Surgery is the primary treatment of early-stage disease.<xref ref-type="bibr" rid="article-31276.r40">[40]</xref>&#x000a0;The risk of recurrence is associated with tumor size, lymph node involvement, and positive margins.<xref ref-type="bibr" rid="article-31276.r41">[41]</xref><xref ref-type="bibr" rid="article-31276.r42">[42]</xref>&#x000a0;For SCC with a depth of invasion &#x02264;1mm, wide-local excision without lymphadenectomy is sufficient with a recommended surgical margin of 1&#x000a0;to 2 cm. If tumor depth is greater than 1mm or tumor diameter exceeds 2 cm, radical resection with margins extending to the perineal fascia and inguinal lymph node assessment should be performed. This more aggressive treatment is recommended due to the risk of occult nodal metastasis and increased risk of death from groin recurrence. For verrucous carcinoma, local excision is typically sufficient; however, the advanced disease may require radical resection.<xref ref-type="bibr" rid="article-31276.r43">[43]</xref> Tumor-free margins decrease the risk of recurrence.<xref ref-type="bibr" rid="article-31276.r44">[44]</xref></p>
        <p>Similarly, wide local excision with tumor-free margins is also recommended for vulvar melanoma as in cutaneous melanoma because radical surgery to treat vulvar melanoma does not improve survival and is associated with increased morbidity.<xref ref-type="bibr" rid="article-31276.r4">[4]</xref>&#x000a0;In vulvar Paget disease, local excision is the standard of care; however, given that multifocal disease is common, high rates of positive margins and recurrence are often observed. Inguinal lymphadenectomy should be considered if the invasion is greater than 1mm. Mohs surgery may benefit the successful resection of Pagetoid lesions and has been associated with a higher rate of negative margins.<xref ref-type="bibr" rid="article-31276.r45">[45]</xref>&#x000a0;In vulvar sarcoma, the standard treatment is radical local excision, with inadequate excision of margins being the most important predictor of recurrence.<xref ref-type="bibr" rid="article-31276.r31">[31]</xref></p>
        <p><bold>Lymph Nodes</bold>: The decision to perform staging lymphadenectomy should be carefully considered based on the risk of occult disease and morbidity. There is no successful treatment for vulvar cancer patients with groin recurrence.<xref ref-type="bibr" rid="article-31276.r46">[46]</xref> while 14&#x000a0;to 48% of vulvar cancer patients experience clinically significant lymphedema after groin dissection.<xref ref-type="bibr" rid="article-31276.r47">[47]</xref> Evaluation of lymph nodes should be performed for vulvar cancers with DOI &#x0003e;1mm.<xref ref-type="bibr" rid="article-31276.r48">[48]</xref>&#x000a0;Factors associated with the potential risk of lymphedema include the duration of follow-up, the surgical procedure used, the cancer stage, the presence of wound infection, elevated BMI, and adjuvant radiation or chemotherapy.<xref ref-type="bibr" rid="article-31276.r49">[49]</xref></p>
        <p>The type of node assessment also impacts morbidity, with those undergoing complete lymphadenectomy at five times higher risk of lymphedema than those undergoing sentinel lymph node (SNL) biopsy.<xref ref-type="bibr" rid="article-31276.r49">[49]</xref> The SLN concept has been proven safe and feasible in specific cancers such as breast cancer, melanoma, and some gynecologic cancers, including vulvar cancer. Studies of SLN mapping in early-stage vulvar cancer have been demonstrated as safe with a high detection rate and high sensitivity.<xref ref-type="bibr" rid="article-31276.r48">[48]</xref><xref ref-type="bibr" rid="article-31276.r50">[50]</xref>&#x000a0;when performed by experienced surgeons and is recommended for newly diagnosed vulvar melanomas.<xref ref-type="bibr" rid="article-31276.r27">[27]</xref> Adjuvant radiation for vulvar cancer patients with metastatic disease to the groin improves survival at the cost of potential lymphedema, making SLN mapping an ideal option for reducing morbidity without diminishing survival.</p>
        <p>Suppose the primary lesion is unilateral (greater than 1cm from the vulvar midline). In that case, an ipsilateral inguinal lymphadenectomy can be performed for vulvar SCC because the risk for contralateral lymph node involvement is less than one percent.<xref ref-type="bibr" rid="article-31276.r51">[51]</xref> For midline lesions, a bilateral lymphadenectomy is recommended. The GOG-173 study prospectively assessed the reliability of sentinel lymph node biopsy in vulvar cancer detection and reported a false-negative predictive value of only 2.0% with primary tumors &#x0003c; 4 cm in diameter vs 7.4% in tumors &#x0003e;4cm in diameter.<xref ref-type="bibr" rid="article-31276.r52">[52]</xref>&#x000a0;If technetium-99 is combined with intraoperative blue dye, the detection rate of sentinel lymph nodes is close to 100%.<xref ref-type="bibr" rid="article-31276.r51">[51]</xref> In patients with unifocal tumors &#x0003c;4cm and clinically negative lymph nodes, SLN biopsy is recommended.<xref ref-type="bibr" rid="article-31276.r53">[53]</xref></p>
        <p>For vulvar BCC, lymph node biopsy is generally not required. In patients with melanoma, SLN biopsy is recommended at the surgical resection of the primary tumor.<xref ref-type="bibr" rid="article-31276.r27">[27]</xref> Bilateral versus unilateral lymph node assessment follows SCC criteria. In patients with verrucous carcinoma, lesions are locally invasive, with reports of tumors up to 15cm in size with little to no risk of lymph node metastasis. However, due to the possible coexistence of SCC with VC and the considerable differences in treatment, an adequately large and deep biopsy should be obtained to rule out concomitant disease. After SCC is excluded, routine lymph node dissection should be omitted for verrucous carcinoma. For vulvar sarcomas, lymph node dissection should be reserved for cases in which lymph nodes are clinically positive. Treatment recommendations for Bartholin gland carcinoma are similar to those for vulvar SCC.<xref ref-type="bibr" rid="article-31276.r34">[34]</xref></p>
      </sec>
      <sec id="article-31276.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>Radiation is recommended for vulvar cancer as adjuvant therapy for histology-confirmed metastatic disease and as primary therapy for locally advanced disease, followed by radical resection of the residual tumor. When SLN biopsy is positive, it is acceptable to offer adjuvant radiation with or without chemotherapy or to perform a complete inguinal lymphadenectomy and offer adjuvant therapy only if high-risk features are identified, such as positive or close resection margins, multifocal disease, multiple involved nodes, or extracapsular extension. The latter approach is recommended, especially if there are &#x02265;2 positive nodes or 1 positive node with &#x0003e;2 mm metastasis.<xref ref-type="bibr" rid="article-31276.r54">[54]</xref><xref ref-type="bibr" rid="article-31276.r55">[55]</xref>&#x000a0;</p>
        <p>Primary chemoradiation is recommended in the case of locally advanced disease, followed by radical resection of any residual disease.<xref ref-type="bibr" rid="article-31276.r56">[56]</xref><xref ref-type="bibr" rid="article-31276.r57">[57]</xref><xref ref-type="bibr" rid="article-31276.r58">[58]</xref>&#x000a0;In the event of distant metastasis, treatment is palliative, primarily focused on improved quality of life. In these cases, chemoradiation can be used for symptomatic relief at the primary tumor site and pelvis.<xref ref-type="bibr" rid="article-31276.r59">[59]</xref> For vulvar melanoma, radiotherapy has a limited benefit, and the use of neoadjuvant radiotherapy has not been described.<xref ref-type="bibr" rid="article-31276.r5">[5]</xref></p>
        <p>In vulvar Paget disease, radiotherapy or photodynamic therapy (PDT) can be considered as an alternative treatment option to surgical resection.<xref ref-type="bibr" rid="article-31276.r2">[2]</xref><xref ref-type="bibr" rid="article-31276.r60">[60]</xref>&#x000a0;PDT is a clinically approved, minimally invasive procedure that involves treatment with a photosensitizing agent, followed by irradiation at a wavelength corresponding to the absorbance band of the sensitizer. PDT is an effective and safe alternative treatment more commonly used for VIN that preserves normal anatomy and sexual function without risk of disease progression.<xref ref-type="bibr" rid="article-31276.r61">[61]</xref></p>
      </sec>
      <sec id="article-31276.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Prospective trials of chemotherapy as a treatment for vulvar cancers are lacking. Recommendations are largely extrapolated from therapeutic trials for metastatic cervical or anal cancers. The agents commonly used are platinum-based chemotherapeutic agents.<xref ref-type="bibr" rid="article-31276.r57">[57]</xref><xref ref-type="bibr" rid="article-31276.r58">[58]</xref><xref ref-type="bibr" rid="article-31276.r59">[59]</xref>&#x000a0;More recent studies have investigated targeted agents. One such agent, Erlotinib, is an anti-epidermal growth factor receptor tyrosine kinase inhibitor and has been tested in vulvar SCC. A partial response was observed in 27% of patients, and an additional 40% exhibited stable disease, but the progression-free survival was poor.<xref ref-type="bibr" rid="article-31276.r62">[62]</xref>&#x000a0;Cemiplimab, a PD-1 blocker, has undergone a Phase-II trial in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma that reported a 47% response rate, of which more than half persisted greater than 6 months, and it is currently approved to treat metastatic cutaneous vulvar SCC.<xref ref-type="bibr" rid="article-31276.r63">[63]</xref></p>
        <p>Suppose surgical excision of SCC or BCC is contraindicated. In that case, an alternative treatment option proven effective in HPV-associated VIN is topical 5% imiquimod cream applied 3 times weekly for 16 weeks.<xref ref-type="bibr" rid="article-31276.r64">[64]</xref>&#x000a0;Treatment with topical 5-fluorouracil and photodynamic therapy may also be considered in BCC. In patients with melanoma, medical management with novel CTLA-4-, PD-1-, BRAF-, and MEK-inhibitors such as nivolumab and ipilimumab has improved overall survival. These therapies are now considered first-line therapy in patients with stage III disease, but limited data is available for the response of vulvar melanoma. One of the differences between cutaneous melanoma and vulvar melanoma is the relatively high number of receptor tyrosine kinase proteins (KIT) mutations. This creates the potential to explore tyrosine kinase inhibitors as a treatment for vulvar melanoma in future studies.<xref ref-type="bibr" rid="article-31276.r65">[65]</xref> While one retrospective study reported a 75% response rate to topical 5% imiquimod cream for the treatment of vulvar Paget disease, the results of a prospective trial are not yet available.<xref ref-type="bibr" rid="article-31276.r66">[66]</xref><xref ref-type="bibr" rid="article-31276.r67">[67]</xref><xref ref-type="bibr" rid="article-31276.r66">[66]</xref></p>
      </sec>
      <sec id="article-31276.s14" sec-type="Staging">
        <title>Staging</title>
        <p>The International Federation of Gynecology and Obstetrics (FIGO) performs vulvar cancer staging surgically.[68] The surgical stage is related to treatment and prognosis.</p>
        <p><bold>Stage I </bold>Tumors confined to the vulva or perineum, no nodal metastasis.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>IA</bold>: Tumor &#x02264;2 cm with stromal invasion &#x02264;1 mm</p>
          </list-item>
          <list-item>
            <p><bold>IB</bold>: Tumor &#x0003e;2 cm or stromal invasion &#x0003e;1 mm</p>
          </list-item>
        </list>
        <p><bold>Stage II </bold>Tumor of any size with extension to adjacent perineal structures (lower urethra, lower vagina, anus), no nodal metastasis</p>
        <p><bold>Stage III </bold>Tumor of any size with or without extension to adjacent perineal structures (lower urethra, lower vagina, anus), with inguinofemoral nodal metastasis</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>IIIA</bold>: 1 node metastasis (&#x02265;5 mm) or 1&#x000a0;to 2 node metastasis(es) (&#x0003c;5 mm)</p>
          </list-item>
          <list-item>
            <p><bold>IIIB</bold>:&#x000a0;&#x02265;2 node metastases (&#x02265;5 mm) or &#x02265; 3 node metastases (&#x0003c;5 mm</p>
          </list-item>
          <list-item>
            <p><bold>IIIC</bold>: node metastases with extra-capsular spread</p>
          </list-item>
        </list>
        <p><bold>Stage IV </bold>Tumor invades other regional or distal structures.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>IVA</bold>: Tumor invades any of the following: upper urethra or vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to the pelvic bone, or fixed or ulcerated inguinofemoral nodes</p>
          </list-item>
          <list-item>
            <p><bold>IVB</bold>: Any distant metastasis, including pelvic nodes</p>
          </list-item>
        </list>
        <p>The exception of FIGO staging of vulvar cancers is melanoma, for which staging is the same as that of cutaneous melanoma and follows the TNM staging system used by the AJCC. The Breslow, Clark, and Chung micro staging systems have been historically used to evaluate pathological characteristics, with Breslow staging affording the most accurate prediction of survival and recurrence.<xref ref-type="bibr" rid="article-31276.r26">[26]</xref> Breslow depth is defined as tumor thickness from the top of the epidermal granular layer to the deepest invasion point.</p>
      </sec>
      <sec id="article-31276.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In vulvar cancer, the lymphatic spread is initially to homolateral superficial inguinal lymph nodes and then to deep femoroinguinal lymph nodes. Lymph node status is the most powerful prognostic factor for overall survival in patients with vulvar cancer. Survival rates are significantly lower for patients with lymph node metastasis: 65% vs 91% at 10 years, 52.5% vs 87.5% at 5 years, and 56.2% vs 90.2% at 3 years. Progression-free survival is better in node-positive patients who receive adjuvant radiotherapy. Overall, the recurrence rate of vulvar cancer is 37% at five years.&#x000a0;Patients diagnosed with distant metastasis have a poor prognosis.<xref ref-type="bibr" rid="article-31276.r68">[68]</xref><xref ref-type="bibr" rid="article-31276.r69">[69]</xref><xref ref-type="bibr" rid="article-31276.r68">[68]</xref>&#x000a0;Vulvar melanoma prognosis is poor, with an estimated 5-year survival of between 10% to 63%.<xref ref-type="bibr" rid="article-31276.r70">[70]</xref> Patients with centrally-located vulva melanoma have a reduced survival rate and a shorter recurrence-free interval.<xref ref-type="bibr" rid="article-31276.r26">[26]</xref><xref ref-type="bibr" rid="article-31276.r71">[71]</xref><xref ref-type="bibr" rid="article-31276.r26">[26]</xref>&#x000a0;The average time to recurrence in vulvar melanoma is 43.5 months, with an overall 50% recurrence rate.<xref ref-type="bibr" rid="article-31276.r72">[72]</xref></p>
        <p>Vulvar Paget disease has a favorable prognosis despite a frequent recurrence rate. In patients with vulvar Paget disease and an underlying adenocarcinoma, the prognosis depends on the type of and treatment outcomes for the associated adenocarcinoma. Local recurrence of vulvar sarcoma is common. The most predictive factors for recurrence are inadequate resection margins and tumor diameter greater than 5mm, infiltrating margins, and high mitotic rate. Bartholin gland carcinoma is similar to vulvar SCC because the prognosis is stage-dependent.<xref ref-type="bibr" rid="article-31276.r34">[34]</xref>&#x000a0;HPV status is also relevant for prognosis as HPV-positive vulvar cancers have more favorable outcomes than HPV-negative and may be exploited to allow for more conservative treatment and post-treatment follow-up.<xref ref-type="bibr" rid="article-31276.r7">[7]</xref>]<xref ref-type="bibr" rid="article-31276.r73">[73]</xref><xref ref-type="bibr" rid="article-31276.r7">[7]</xref>&#x000a0;Recurrent disease confined to the vulva can be successfully treated with surgical resection. However, patients with metastatic or locally-aggressive recurrence of vulvar cancer have a 2-year overall survival of only 57% after exenterative surgery.<xref ref-type="bibr" rid="article-31276.r74">[74]</xref></p>
      </sec>
      <sec id="article-31276.s16" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of vulvar cancer include the results of the disease process itself and the results of the treatment and management. Complications of vulvar cancer include worsening pain and irritation and declining functional status as the malignancy spreads and begins to invade locally and regionally. Complications of surgery are many and can include infection, critical blood loss, lower extremity lymphedema, significant chronic pain, as well as associated organ complications&#x000a0;in the event of additional procedures needed to resect disease optimally. Complications of chemotherapy and radiation include susceptibility to infection, multiple gastrointestinal reactions, as well as tissue fibrosis and lymphedema.</p>
      </sec>
      <sec id="article-31276.s17" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Due to the significant rate of recurrent patients, they should be followed closely after treatment. Follow-up surveillance should be every three months for two years, every six months for 3 years, and annually afterward.<xref ref-type="bibr" rid="article-31276.r75">[75]</xref></p>
      </sec>
      <sec id="article-31276.s18" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated on the nature of the disease process and the importance of close follow-up. Patients should also be educated on the best treatment options and the associated risks with each treatment modality. Finally, after treatment, patient education should focus on the need for routine surveillance and general healthcare maintenance and follow-up.</p>
      </sec>
      <sec id="article-31276.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A multidisciplinary approach to vulvar cancer should commence upon diagnosis with input from gynecologic oncology, medical oncology, and radiation oncology teams. An emphasis should be placed on early diagnosis and treatment, with close post-treatment surveillance. Patients should be encouraged to receive the HPV vaccine early in life to reduce their overall risk of contracting the HPV virus and thus reduce their risk of contracting HPV-dependent vulvar cancer. The HPV vaccine may also have a therapeutic role in early VIN. However, more studies are needed to investigate the potential therapeutic impact of vulvar carcinoma.<xref ref-type="bibr" rid="article-31276.r76">[76]</xref></p>
      </sec>
      <sec id="article-31276.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31276&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31276">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/vulva-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31276">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31276/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31276">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-31276.s21">
        <fig id="article-31276.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Kraurosis Vulvae, Lichen Sclerosus, Pathology. Lichen sclerosus is a chronic inflammatory dermatosis that presents as small white raised patches on the genital area. Contributed by NJ Fiumara, MD, Centers for Disease Control and Prevention</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PHIL_4092_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-31276.s22">
        <fig id="article-31276.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Vulvar Cancer Development Adapted and Contributed by Gerson Cordero Rubio, Department of Histology, Jagiellonian University Medical College; Remy Brossel (CC BY-SA 4.0 https://creativecommons.org/licenses/by-sa/4.0/deed.en)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Vulvular__Cancer__Develpoment__HPV__" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-31276.s23">
        <fig id="article-31276.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Vulvar Squamous Cell Carcinoma. Histopathology slide of vulvar squamous cell carcinoma, low power field, H&#x00026;E stain. Contributed by WL Ward, MD&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="low__power-p1esjhdnar1gob7091rdv1j4c1bqj" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-31276.s24">
        <fig id="article-31276.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Vulvar Squamous Cell Carcinoma, Histopathology. This is a histopathology image of a low-power field H&#x00026;E stain of Vulvar Squamous Cell Carcinoma, showing keratinized pearls. Contributed by WL Ward, MD&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Squamous__carcinoma__vulva-p1esjj75vf173t1pj61klhjjpno2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-31276.s25">
        <fig id="article-31276.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Human Papillomavirus (HPV 16).&#x000a0;The histopathology slide of vulvar squamous cell carcinoma with P16 stain shows&#x000a0;positivity for human papillomavirus (HPV 16). Contributed by WL Ward, MD&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="P16__converted" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-31276.s26">
        <title>References</title>
        <ref id="article-31276.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rauh</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lachiewicz</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>IR</given-names>
              </name>
            </person-group>
            <article-title>Margins for cervical and vulvar cancer.</article-title>
            <source>J Surg Oncol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>113</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <page-range>304-9</page-range>
            <pub-id pub-id-type="pmid">26852901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wohlmuth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wohlmuth-Wieser</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Vulvar malignancies: an interdisciplinary perspective.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>1257</fpage>
            <page-range>1257-1276</page-range>
            <pub-id pub-id-type="pmid">31829526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canavan</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Vulvar cancer.</article-title>
            <source>Am Fam Physician</source>
            <year>2002</year>
            <month>Oct</month>
            <day>01</day>
            <volume>66</volume>
            <issue>7</issue>
            <fpage>1269</fpage>
            <page-range>1269-74</page-range>
            <pub-id pub-id-type="pmid">12387439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boer</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Ten Eikelder</surname>
                <given-names>MLG</given-names>
              </name>
              <name>
                <surname>Kapiteijn</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Creutzberg</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Galaal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Poelgeest</surname>
                <given-names>MIE</given-names>
              </name>
            </person-group>
            <article-title>Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>73</volume>
            <fpage>91</fpage>
            <page-range>91-103</page-range>
            <pub-id pub-id-type="pmid">30685613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gomez-Martinez</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Vulvar Cancer.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-135</page-range>
            <pub-id pub-id-type="pmid">30683259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faber</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Albieri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Norrild</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kjaer</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Verdoodt</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva.</article-title>
            <source>Int J Cancer</source>
            <year>2017</year>
            <month>Sep</month>
            <day>15</day>
            <volume>141</volume>
            <issue>6</issue>
            <fpage>1161</fpage>
            <page-range>1161-1169</page-range>
            <pub-id pub-id-type="pmid">28577297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of human papillomavirus and its prognostic value in vulvar cancer: A systematic review and meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>e0204162</fpage>
            <pub-id pub-id-type="pmid">30256833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clancy</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Spaans</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Weberpals</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy.</article-title>
            <source>Ann Oncol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>1696</fpage>
            <page-range>1696-705</page-range>
            <pub-id pub-id-type="pmid">27329249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allbritton</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Vulvar Neoplasms, Benign and Malignant.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>339</fpage>
            <page-range>339-352</page-range>
            <pub-id pub-id-type="pmid">28778635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bornstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bogliatto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haefner</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Stockdale</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Preti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bohl</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Reutter</surname>
                <given-names>J</given-names>
              </name>
              <collab>ISSVD Terminology Committee</collab>
            </person-group>
            <article-title>The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of Vulvar Squamous Intraepithelial Lesions.</article-title>
            <source>J Low Genit Tract Dis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-4</page-range>
            <pub-id pub-id-type="pmid">26704327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pomeranz</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of vulvar cancer: A review.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>81</volume>
            <issue>6</issue>
            <fpage>1387</fpage>
            <page-range>1387-1396</page-range>
            <pub-id pub-id-type="pmid">31349045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dasgupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ewing-Graham</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Swagemakers</surname>
                <given-names>SMA</given-names>
              </name>
              <name>
                <surname>van der Spek</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>van Doorn</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Noordhoek Hegt</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Koljenovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Kemenade</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Precursor lesions of vulvar squamous cell carcinoma - histology and biomarkers: A systematic review.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>147</volume>
            <fpage>102866</fpage>
            <pub-id pub-id-type="pmid">32058913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Micheletti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Preti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radici</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boveri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Pumpo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Privitera</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ghiringhello</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benedetto</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Vulvar Lichen Sclerosus and Neoplastic Transformation: A Retrospective Study of 976 Cases.</article-title>
            <source>J Low Genit Tract Dis</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>180</fpage>
            <page-range>180-3</page-range>
            <pub-id pub-id-type="pmid">26882123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuurman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>van den Einden</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Massuger</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Kiemeney</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>van der Aa</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>de Hullu</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma.</article-title>
            <source>Eur J Cancer</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>18</issue>
            <fpage>3872</fpage>
            <page-range>3872-80</page-range>
            <pub-id pub-id-type="pmid">24011936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abdul-Wahab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calonje</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Craythorne</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Basal cell carcinoma of the vulva: treatment with Mohs micrographic surgery.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>651</fpage>
            <page-range>651-653</page-range>
            <pub-id pub-id-type="pmid">30618159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chanda</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Extramammary Paget's disease: prognosis and relationship to internal malignancy.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1985</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>1009</fpage>
            <page-range>1009-14</page-range>
            <pub-id pub-id-type="pmid">3001158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Mammary and extramammary Paget's disease.</article-title>
            <source>J Clin Pathol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>742</fpage>
            <page-range>742-9</page-range>
            <pub-id pub-id-type="pmid">11064666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Crandon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanday</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Paget's disease of the vulva: Diagnosis and follow-up key to management; a retrospective study of 50 cases from Queensland.</article-title>
            <source>Gynecol Oncol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>122</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-4</page-range>
            <pub-id pub-id-type="pmid">21501860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bodurka-Bevers</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Deavers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bevers</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Shen-Gunther</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gershenson</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Paget's disease of the vulva: pathology, pattern of involvement, and prognosis.</article-title>
            <source>Gynecol Oncol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <page-range>183-9</page-range>
            <pub-id pub-id-type="pmid">10739709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St Claire</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ashack</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Khachemoune</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Extramammary Paget disease.</article-title>
            <source>Dermatol Online J</source>
            <year>2019</year>
            <month>Apr</month>
            <day>15</day>
            <volume>25</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31046904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Primary extramammary Paget's disease of the vulva: the clinicopathological features and treatment outcomes in a series of 43 patients.</article-title>
            <source>Gynecol Oncol</source>
            <year>2013</year>
            <month>May</month>
            <volume>129</volume>
            <issue>2</issue>
            <fpage>412</fpage>
            <page-range>412-6</page-range>
            <pub-id pub-id-type="pmid">23454498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konstantinova</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shelekhova</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Spagnolo</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Kutzner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kacerovska</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Plaza</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Suster</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bouda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pavlovsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kyrpychova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Michal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guenova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kazakov</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Depth and Patterns of Adnexal Involvement in Primary Extramammary (Anogenital) Paget Disease: A Study of 178 Lesions From 146 Patients.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>802</fpage>
            <page-range>802-808</page-range>
            <pub-id pub-id-type="pmid">26863064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ragnarsson-Olding</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Kanter-Lewensohn</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Lagerl&#x000f6;f</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ringborg</surname>
                <given-names>UK</given-names>
              </name>
            </person-group>
            <article-title>Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival.</article-title>
            <source>Cancer</source>
            <year>1999</year>
            <month>Oct</month>
            <day>01</day>
            <volume>86</volume>
            <issue>7</issue>
            <fpage>1285</fpage>
            <page-range>1285-93</page-range>
            <pub-id pub-id-type="pmid">10506715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rouzbahman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kamel-Reid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al Habeeb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dodge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laframboise</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rasty</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ghazarian</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.</article-title>
            <source>J Low Genit Tract Dis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>350</fpage>
            <page-range>350-3</page-range>
            <pub-id pub-id-type="pmid">26225944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hou</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Baptiste</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hombalegowda</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Tergas</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Chatterjee-Paer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bus-Kwolfski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Apr</month>
            <day>15</day>
            <volume>123</volume>
            <issue>8</issue>
            <fpage>1333</fpage>
            <page-range>1333-1344</page-range>
            <pub-id pub-id-type="pmid">28026870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Bundy</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Okagaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kucera</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Stehman</surname>
                <given-names>FB</given-names>
              </name>
            </person-group>
            <article-title>Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group.</article-title>
            <source>Cancer</source>
            <year>1994</year>
            <month>May</month>
            <day>15</day>
            <volume>73</volume>
            <issue>10</issue>
            <fpage>2626</fpage>
            <page-range>2626-32</page-range>
            <pub-id pub-id-type="pmid">8174062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leitao</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Management of vulvar and vaginal melanomas: current and future strategies.</article-title>
            <source>Am Soc Clin Oncol Educ Book</source>
            <year>2014</year>
            <fpage>e277</fpage>
            <page-range>e277-81</page-range>
            <pub-id pub-id-type="pmid">24857113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nascimento</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Granter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cviko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hecht</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Crum</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Vulvar acanthosis with altered differentiation: a precursor to verrucous carcinoma?</article-title>
            <source>Am J Surg Pathol</source>
            <year>2004</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>638</fpage>
            <page-range>638-43</page-range>
            <pub-id pub-id-type="pmid">15105653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Brennick</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Immunohistochemical patterns of ProEx C in vulvar squamous lesions: detection of overexpression of MCM2 and TOP2A.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>1250</fpage>
            <page-range>1250-7</page-range>
            <pub-id pub-id-type="pmid">20697251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gualco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Foglia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fulcheri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Odicino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Prefumo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stanta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ragni</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Morphologic and biologic studies on ten cases of verrucous carcinoma of the vulva supporting the theory of a discrete clinico-pathologic entity.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2003</year>
            <season>May-Jun</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-24</page-range>
            <pub-id pub-id-type="pmid">12801263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aartsen</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Albus-Lutter</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Vulvar sarcoma: clinical implications.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-9</page-range>
            <pub-id pub-id-type="pmid">7821491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Detty</surname>
                <given-names>SQ</given-names>
              </name>
              <name>
                <surname>Gonzaga</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Huerter</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features and Treatment of Dermatofibrosarcoma Protuberans Affecting the Vulva: A Literature Review.</article-title>
            <source>Dermatol Surg</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>771</fpage>
            <page-range>771-774</page-range>
            <pub-id pub-id-type="pmid">28323651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iavazzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gkegkes</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Vrachnis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Dilemmas in the management of patients with vulval epithelioid sarcoma: a literature review.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2014</year>
            <month>May</month>
            <volume>176</volume>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">24636595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhalwal</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Nick</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dos Reis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Munsell</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ramalingam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salcedo</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Schmeler</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Carcinoma of the Bartholin Gland: A Review of 33 Cases.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2016</year>
            <month>May</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>785</fpage>
            <page-range>785-9</page-range>
            <pub-id pub-id-type="pmid">26844611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nazeran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Karnezis</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Tinker</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Gilks</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome.</article-title>
            <source>Int J Gynecol Pathol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-195</page-range>
            <pub-id pub-id-type="pmid">29406447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pigmented vulvar lesions.</article-title>
            <source>Dermatol Ther</source>
            <year>2010</year>
            <season>Sep-Oct</season>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>449</fpage>
            <page-range>449-57</page-range>
            <pub-id pub-id-type="pmid">20868400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koh</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Abu-Rustum</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Chon</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crispens</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dizon</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Dorigo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Eifel</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Frederick</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gaffney</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Lurain</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mutch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nagel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nekhlyudov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fader</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Remmenga</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Tillmanns</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valea</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Wyse</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yashar</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McMillian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scavone</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-120</page-range>
            <pub-id pub-id-type="pmid">28040721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rigel</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Carucci</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Malignant melanoma: prevention, early detection, and treatment in the 21st century.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2000</year>
            <season>Jul-Aug</season>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>215</fpage>
            <page-range>215-36; quiz 237-40</page-range>
            <pub-id pub-id-type="pmid">10986965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmitt</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>McGree</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bakkum-Gamez</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Cliby</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Screening Recommendations for Occult Cancers in the Setting of Newly Diagnosed Extramammary Paget Disease.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>93</volume>
            <issue>7</issue>
            <fpage>877</fpage>
            <page-range>877-883</page-range>
            <pub-id pub-id-type="pmid">29804724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ansink</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Surgical interventions for early squamous cell carcinoma of the vulva.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2000</year>
            <volume>2000</volume>
            <issue>2</issue>
            <fpage>CD002036</fpage>
            <pub-id pub-id-type="pmid">10796849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maggino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Landoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sartori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gadducci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alessi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sold&#x000e0;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coscio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spinetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maneo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Konishi De Toffoli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study.</article-title>
            <source>Cancer</source>
            <year>2000</year>
            <month>Jul</month>
            <day>01</day>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>116</fpage>
            <page-range>116-22</page-range>
            <pub-id pub-id-type="pmid">10897008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCann</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Taege</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Boutsicaris</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Eisenhauer</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>O'Malley</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Salani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.</article-title>
            <source>Gynecol Oncol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-48</page-range>
            <pub-id pub-id-type="pmid">23138134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Pomel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Exenterative surgery for recurrent gynaecological malignancies.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Feb</month>
            <day>04</day>
            <volume>2014</volume>
            <issue>2</issue>
            <fpage>CD010449</fpage>
            <pub-id pub-id-type="pmid">24497188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Verrucous Carcinoma of the Vulva: A Case Report and Literature Review.</article-title>
            <source>Am J Case Rep</source>
            <year>2019</year>
            <month>Apr</month>
            <day>19</day>
            <volume>20</volume>
            <fpage>551</fpage>
            <page-range>551-556</page-range>
            <pub-id pub-id-type="pmid">31002657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Long</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>McGree</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bakkum-Gamez</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cliby</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>A matter of margins: Surgical and pathologic risk factors for recurrence in extramammary Paget's disease.</article-title>
            <source>Gynecol Oncol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>147</volume>
            <issue>2</issue>
            <fpage>358</fpage>
            <page-range>358-363</page-range>
            <pub-id pub-id-type="pmid">28935274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stehman</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Bundy</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Clarke-Pearson</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>174</volume>
            <issue>4</issue>
            <fpage>1128</fpage>
            <page-range>1128-32; discussion 1132-3</page-range>
            <pub-id pub-id-type="pmid">8623839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wills</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Obermair</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review of complications associated with the surgical treatment of vulvar cancer.</article-title>
            <source>Gynecol Oncol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>131</volume>
            <issue>2</issue>
            <fpage>467</fpage>
            <page-range>467-79</page-range>
            <pub-id pub-id-type="pmid">23863358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawrie</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin-Hirsch</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ratnavelu</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ralte</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Sentinel node assessment for diagnosis of groin lymph node involvement in vulval cancer.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Jun</month>
            <day>27</day>
            <volume>2014</volume>
            <issue>6</issue>
            <fpage>CD010409</fpage>
            <pub-id pub-id-type="pmid">24970683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Incidence of lower limb lymphedema after vulvar cancer: A systematic review and meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>96</volume>
            <issue>46</issue>
            <fpage>e8722</fpage>
            <pub-id pub-id-type="pmid">29145314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skanjeti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhomps</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paschetta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tordo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giammarile</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Sentinel Node Mapping in Gynecologic Cancers: A Comprehensive Review.</article-title>
            <source>Semin Nucl Med</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>521</fpage>
            <page-range>521-533</page-range>
            <pub-id pub-id-type="pmid">31630736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Hullu</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>van der Zee</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Surgery and radiotherapy in vulvar cancer.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-58</page-range>
            <pub-id pub-id-type="pmid">16829120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levenback</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>De Geest</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Spirtos</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Potkul</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Leitao</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bakkum-Gamez</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Lentz</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Van Le</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Trimble</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Nov</month>
            <day>01</day>
            <volume>30</volume>
            <issue>31</issue>
            <fpage>3786</fpage>
            <page-range>3786-91</page-range>
            <pub-id pub-id-type="pmid">22753905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Covens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vella</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Reade</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Sentinel lymph node biopsy in vulvar cancer: Systematic review, meta-analysis and guideline recommendations.</article-title>
            <source>Gynecol Oncol</source>
            <year>2015</year>
            <month>May</month>
            <volume>137</volume>
            <issue>2</issue>
            <fpage>351</fpage>
            <page-range>351-61</page-range>
            <pub-id pub-id-type="pmid">25703673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Balasubramani</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sukumvanich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krivak</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Olawaiye</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Beriwal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis.</article-title>
            <source>Gynecol Oncol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>137</volume>
            <issue>3</issue>
            <fpage>365</fpage>
            <page-range>365-72</page-range>
            <pub-id pub-id-type="pmid">25868965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jueckstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hilpert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Neuser</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Gregorio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hasenburg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sehouli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hillemanns</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fuerst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mustea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Griebel</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Woelber</surname>
                <given-names>L</given-names>
              </name>
              <collab>AGO-CaRE 1 investigators</collab>
            </person-group>
            <article-title>Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>107</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">25618900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ignatov</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eggemann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ignatov</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>142</volume>
            <issue>2</issue>
            <fpage>489</fpage>
            <page-range>489-95</page-range>
            <pub-id pub-id-type="pmid">26498775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montana</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Saxer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mangan</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Lentz</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Averette</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2000</year>
            <month>Nov</month>
            <day>01</day>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>1007</fpage>
            <page-range>1007-13</page-range>
            <pub-id pub-id-type="pmid">11072157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Montana</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Saxer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gallup</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Olt</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>1998</year>
            <month>Aug</month>
            <day>01</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-85</page-range>
            <pub-id pub-id-type="pmid">9747823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>McCourt</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Homesley</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study.</article-title>
            <source>Gynecol Oncol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>529</fpage>
            <page-range>529-33</page-range>
            <pub-id pub-id-type="pmid">22079361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tagliaferri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cas&#x000e0;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Macchia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pesce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garganese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gui</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gentileschi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inzani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Autorino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cammelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morganti</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gambacorta</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The Role of Radiotherapy in Extramammary Paget Disease: A Systematic Review.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2018</year>
            <month>May</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>829</fpage>
            <page-range>829-839</page-range>
            <pub-id pub-id-type="pmid">29538255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Photodynamic therapy for treatment of usual-type vulvar intraepithelial neoplasia: a case report and literature review.</article-title>
            <source>J Int Med Res</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>47</volume>
            <issue>8</issue>
            <fpage>4019</fpage>
            <page-range>4019-4026</page-range>
            <pub-id pub-id-type="pmid">31364444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horowitz</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Olawaiye</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Borger</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Growdon</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Krasner</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Matulonis</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dizon</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.</article-title>
            <source>Gynecol Oncol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-6</page-range>
            <pub-id pub-id-type="pmid">22750258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Migden</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rischin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmults</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Guminski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hauschild</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Hernandez-Aya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>ALS</given-names>
              </name>
              <name>
                <surname>Rabinowits</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thai</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>BGM</given-names>
              </name>
              <name>
                <surname>Khushalani</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Modi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Seebach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mathias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stankevich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Babiker</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Brana</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gil-Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Homsi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Owonikoko</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Lowy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fury</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jul</month>
            <day>26</day>
            <volume>379</volume>
            <issue>4</issue>
            <fpage>341</fpage>
            <page-range>341-351</page-range>
            <pub-id pub-id-type="pmid">29863979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terlou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Seters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kleinjan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heijmans-Antonissen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santegoets</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Beckmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>van Beurden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Helmerhorst</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Blok</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia.</article-title>
            <source>Int J Cancer</source>
            <year>2010</year>
            <month>Dec</month>
            <day>15</day>
            <volume>127</volume>
            <issue>12</issue>
            <fpage>2831</fpage>
            <page-range>2831-40</page-range>
            <pub-id pub-id-type="pmid">21351262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wan</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ming</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56.</article-title>
            <source>Br J Dermatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>179</volume>
            <issue>2</issue>
            <fpage>296</fpage>
            <page-range>296-300</page-range>
            <pub-id pub-id-type="pmid">29766492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Linden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meeuwis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Hees</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Dorst</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bulten</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bosse</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>IntHout</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boll</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Slangen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Seters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Beurden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Poelgeest</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Hullu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease.</article-title>
            <source>JMIR Res Protoc</source>
            <year>2017</year>
            <month>Sep</month>
            <day>06</day>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>e178</fpage>
            <pub-id pub-id-type="pmid">28877863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edey</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Murdoch</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Interventions for the treatment of Paget's disease of the vulva.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Jun</month>
            <day>05</day>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>CD009245</fpage>
            <pub-id pub-id-type="pmid">31167037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Te Grootenhuis</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>van der Zee</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>van Doorn</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vergote</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zanagnolo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gaarenstroom</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>van Dorst</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Trum</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Slangen</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Runnebaum</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Tamussino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hermans</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Provencher</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>de Bock</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>de Hullu</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Oonk</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.</article-title>
            <source>Gynecol Oncol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>140</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">26428940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canlorbe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rouzier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bendifallah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ch&#x000e9;reau</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Impact of sentinel node technique on the survival in patients with vulvar cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database].</article-title>
            <source>Gynecol Obstet Fertil</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>647</fpage>
            <page-range>647-51</page-range>
            <pub-id pub-id-type="pmid">22985904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heinzelmann-Schwarz</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Nixdorf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valadan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diczbalis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Otton</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fedier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hacker</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Scurry</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker.</article-title>
            <source>Int J Mol Med</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>784</fpage>
            <page-range>784-94</page-range>
            <pub-id pub-id-type="pmid">24535703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheistr&#x000f8;en</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trop&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koern</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pettersen</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Abeler</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Malignant melanoma of the vulva. Evaluation of prognostic factors with emphasis on DNA ploidy in 75 patients.</article-title>
            <source>Cancer</source>
            <year>1995</year>
            <month>Jan</month>
            <day>01</day>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-80</page-range>
            <pub-id pub-id-type="pmid">7804980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iacoponi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oehler</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Diez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diaz-De la Noval</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gardella</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kotsopoulos</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Zalewski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zapardiel</surname>
                <given-names>I</given-names>
              </name>
              <collab>VULCAN Study collaborative group</collab>
            </person-group>
            <article-title>Prognostic Factors of Recurrence and Survival in Vulvar Melanoma: Subgroup Analysis of the VULvar CANcer Study.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>1307</fpage>
            <page-range>1307-12</page-range>
            <pub-id pub-id-type="pmid">27465889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rasmussen</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Hoffmann Frederiksen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaae Andersen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kjaer</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Does HPV status influence survival after vulvar cancer?</article-title>
            <source>Int J Cancer</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>142</volume>
            <issue>6</issue>
            <fpage>1158</fpage>
            <page-range>1158-1165</page-range>
            <pub-id pub-id-type="pmid">29090456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nooij</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Gaarenstroom</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Creutzberg</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>de Hullu</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>van Poelgeest</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Risk factors and treatment for recurrent vulvar squamous cell carcinoma.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>106</volume>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">27637349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Frimer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bristow</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.</article-title>
            <source>Gynecol Oncol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>146</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">28372871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31276.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bryan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olaitan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HPV vaccine in the treatment of usual type vulval and vaginal intraepithelial neoplasia: a systematic review.</article-title>
            <source>BMC Womens Health</source>
            <year>2019</year>
            <month>Jan</month>
            <day>07</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">30616555</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
